课题基金 / 基金详情

Oscillatory expression of lentiviral transgenes

Oscillatory expression of lentiviral transgenes
慢病毒转基因的振荡表达
批准号:
2733905
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Although antiretroviral drugs can give people a normal life expectancy after HIV infection, they will still have HIV-infected cells throughout their life that make viruses and compromise their health. By contrast, in the field of gene therapy technology, cells that have been genetically instructed to continually make lentivirus frequently inactivate their viral genes and stop making virus, compromising the effetiveness of gene therapy production. The project aims to model, design, build and test a 'viroscillator' genetic circuit to extend the productive lifespan of stable lentiviral packaging cells. The performance of the resulting cells will be tested against conventional stable lentiviral packaging cell lines. The natural lentivirus, HIV-1, can achieve robust, persistent production of infectious viral particles in infected humans over decades, despite the fact high levels of expression of HIV-1 genes can lead to cell death. Insights gained from mathematical modelling of this system suggested opposing function of two HIV-1 genes act as positive and negative feedback loops respectively to bring about oscillation of viral genes overall. In this way the rate of production of lentiviral genes products is in constant flux, achieving sufficient yield of lentiviral protein over time, but never remaining at cytoxic production rate for long enough to select for a cell response. This project will test the hypothesis that an engineered oscillation of lentiviral genes can extend the productive lifespan of a stable lentiviral packaging cell lines.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
缺氧诱导因子(HIF)-2α转录抑制树突状细胞CD36表达减轻肾脏缺血再灌注损伤的机制
  • 批准号:
    82370751
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    张明
  • 依托单位:
内源性蛋白酶抑制剂SerpinA3N对缺血性脑卒中后血脑屏障的保护作用及其表达调控机制
  • 批准号:
    82371317
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    万杰清
  • 依托单位:
22q11.2染色体微重复影响TOP3B表达并导致腭裂发生的机制研究
  • 批准号:
    82370906
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    代杰文
  • 依托单位:
基于FCER1G基因介导免疫反应探讨迟发性聋与认知障碍相关性的机制研究
  • 批准号:
    82371141
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    陈颖
  • 依托单位: